Clinical Trials Directory

Trials / Completed

CompletedNCT01906853

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in Infants

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,272 (actual)
Sponsor
Murdoch Childrens Research Institute · Academic / Other
Sex
All
Age
10 Days
Healthy volunteers
Accepted

Summary

1. To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life. 2. To evaluate the immunological mechanisms underlying the non-specific effects of BCG by comparing markers of immunity between the BCG and non-BCG groups.

Detailed description

There has been a dramatic rise in allergic diseases worldwide since the 1980s. Asthma rates increased first, followed by eczema, allergic rhinitis and, more recently, food allergy - especially in infants and young children. In Australia, the prevalence of allergic disease is particularly high: up to 30% of children are affected, and eczema and asthma are among the most common chronic diseases of childhood. Preventing allergic disease by an immunomodulatory intervention early in life would be a major advance with significant implications for individual health and public health resources. Bacillus Calmette-Guérin (BCG) immunisation is a potential intervention with an established safety profile. This vaccine has powerful non-specific effects on the cellular immune response that potentially prime host immunity away from an allergic pathway. Observational data and one small randomised controlled trial (RCT) suggest that BCG immunisation at birth leads to a substantial reduction in allergic disease - however, there is an absence of level 1 evidence.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBCG

Timeline

Start date
2013-07-01
Primary completion
2023-09-01
Completion
2025-02-01
First posted
2013-07-24
Last updated
2025-02-17

Locations

2 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT01906853. Inclusion in this directory is not an endorsement.